Explore answers to common questions about OncoFirm™ Diagnostics’ fluorescent and lateral flow rapid test technologies, including how these platforms work, biomarker detection, digital reader integration, potential research applications, performance considerations, and regulatory pathways. This FAQ category is intended for general educational and informational purposes and does not represent that any specific OncoFirm™ product is cleared, approved, CE marked, or authorized for clinical use unless expressly stated.
Provide results typically in 5–15 minutes, enabling immediate clinical decisions.
No lab equipment required; can be performed by non-specialists with minimal training.
Low manufacturing and operational costs make them ideal for large-scale screening and use in resource-limited settings.
Compact, lightweight design makes LFTs ideal for point-of-care, home, and mobile clinics.
Often use blood from a finger prick, saliva, urine, or nasal swabs, improving patient comfort and compliance.
Used across multiple fields:
Infectious diseases (COVID-19, flu, HIV)
Chronic conditions (cardiac markers, kidney disease)
Cancer screening (via tumor markers like PSA, CEA, AFP)
Pregnancy and fertility (hCG, LH tests)
Environmental and food safety
Essential in rural or underserved areas without access to centralized labs.
Early detection of disease leads to better outcomes, reduced hospitalizations, and lower healthcare costs.
Can be integrated with smartphone apps or reader devices for enhanced accuracy, tracking, and remote monitoring.
Widely used and trusted globally with decades of use in diagnostics—especially in public health campaigns and pandemic response.
How fluorescent lateral flow compares with central-lab and visual rapid tests for cancer biomarkers: speed, accuracy, cost, workflow and what to validate.
20.6 million cancer cases a year, yet half the world lacks basic diagnostics. The 2026 evidence on access gaps, survival inequity and what affordable tests need